Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04373031Phase 2Active Not Recruiting

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Role: collaborator

NCT00578240Active Not Recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Role: collaborator

NCT03381183Phase 1Completed

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Role: collaborator

NCT02950259Phase 1Completed

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Role: collaborator

NCT03267680Phase 2Terminated

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Role: collaborator

NCT02609386Phase 2Completed

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Role: lead

NCT00210470Phase 2Completed

A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

Role: lead

NCT03575234Phase 1Withdrawn

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Role: collaborator

All 8 trials loaded